Draig Therapeutics has launched with a $140 million Series A investment to advance next-generation therapies for major neuropsychiatric disorders, including major depressive disorder. The company’s lead programme focuses on DT-101, a positive allosteric modulator of the AMPA receptor, which is currently in Phase II clinical development.

The investment will also support the progression of two selective GABA receptor modulators. Draig Therapeutics aims to develop treatments that address the limitations of current therapies for neuropsychiatric conditions, with a focus on improving clinical outcomes for patients.